Vasculitis & polymyalgia rheumatica
Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide
Authors' conclusion
This subgroup analysis of patients who received CYC shows similar rates of remission in the avacopan and prednisone taper groups.
Study context
- Population
- Patients with AAV (granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)) receiving CYC followed by AZA (or MMF) in the ADVOCATE trial35.2% of 330 treated
- Participants
- 116 patients
- Comparison
- Avacopan vs prednisone taper in AAV patients receiving CYC
- Avacopann = 59
- Prednisone tapern = 57reference
- Primary endpoint
- Key efficacy outcomes: remission at week 26 and sustained remission at week 52
- Follow-up
- Week 26; week 52
Methodological detailssubgroup analysis
- Subgroup analysis
Primary result
As reported in the abstract
Remission · week 26
Further findings
Sustained remission (key efficacy outcome) · week 52
Relapses · over 52 weeks
Estimated glomerular filtration rate (eGFR), albuminuria and GC toxicity
- Improvement in eGFR, speed of albuminuria reduction and differences in GC toxicity favoured the avacopan group
Safety
Serious adverse events
Original publication
Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide. RMD Open. Published 5 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →